Key Takeaways
- Zealand Pharma shares plummeted approximately 25% following Phase III survodutide trial results that exposed elevated patient dropout figures
- Between 23% and 25% of trial participants discontinued survodutide treatment because of gastrointestinal adverse reactions, compared with only 5.4% in the placebo group
- The trial demonstrated weight reduction reaching 16.6% against 3.2% for placebo, showing strong efficacy despite safety concerns
- Goldman Sachs cautioned that poor tolerability could significantly restrict the drug’s commercial success in obesity therapeutics
- Wolfe Research maintained its bullish stance with an “outperform” rating and DKK750 target, suggesting potential gains exceeding 129% from pre-decline pricing
Zealand Pharma (ZEAL) experienced a devastating market capitalization loss of approximately 25% on Monday after releasing Phase III clinical trial results for survodutide, its obesity treatment developed alongside Boehringer Ingelheim, which disclosed that nearly 25% of trial participants discontinued therapy owing to adverse reactions.
Shares declined roughly 25% during Copenhagen exchange trading. Novo Nordisk, Zealand’s primary competitor in obesity pharmaceuticals, simultaneously dropped approximately 2% during the session.
The SYNCHRONIZE-1 clinical study extended 76 weeks and enrolled 725 adult participants with obesity or overweight conditions but without Type 2 diabetes. Weight reduction achieved up to 16.6% using the efficacy estimand compared to 3.2% in the placebo cohort — representing impressive headline numbers.
However, the safety and tolerability profile painted a concerning picture.
Treatment discontinuation percentages reached 23.7% and 24.8% for the 3.6mg and 6mg dosage levels respectively, dramatically exceeding the 5.4% discontinuation rate observed with placebo. The primary driver: gastrointestinal adverse events, which accounted for 17.8% and 20.2% of dropouts across each active dose level versus merely 2.9% in the placebo arm.
Goldman Sachs analysts directly addressed these figures, indicating that suboptimal tolerability will probably constrain survodutide’s commercial adoption within the competitive obesity treatment marketplace.
Wolfe Research identified an additional confounding factor. Approximately 16.5% of placebo-assigned participants utilized a prohibited GLP-1 receptor agonist throughout the study period, artificially elevating placebo group weight loss and diminishing the observable treatment effect difference.
The research firm additionally highlighted how the study’s inflexible protocol design contributed to elevated discontinuation numbers, referencing investigator commentary regarding the conflict between maintaining strict versus adaptable trial parameters.
Impressive Efficacy Results Provide Counterbalance
Notwithstanding the tolerability challenges, the efficacy data contained several noteworthy positives.
A body composition substudy utilizing MRI scanning in 75 participants demonstrated that survodutide 6mg generated a 34% relative decrease in visceral adipose tissue versus 11.8% for placebo. Hepatic fat content declined 63.1% compared to 24.5% in the control group, and lean tissue represented no more than 10.8% of aggregate tissue mass variation at the maximum dosage.
The companion SYNCHRONIZE-MASLD trial, conducted over 48 weeks in 218 adults with obesity and metabolic-associated liver disease, similarly produced positive outcomes. Up to 84.2% of survodutide-treated patients achieved at least a 30% relative liver fat reduction, versus 24.3% receiving placebo. Body mass decreased 12.2% compared to 1% with placebo.
Commercial Prospects Remain for Zealand
Zealand Pharma stands to receive high single-digit to low double-digit royalty percentages on worldwide survodutide revenues, alongside €315 million in remaining milestone payment opportunities. Boehringer Ingelheim maintains complete responsibility for clinical development and market commercialization activities.
Wolfe Research preserved its “outperform” recommendation with a DKK750 price objective — representing approximately 130% upside potential from the pre-decline closing price.
Separately, Novo Nordisk disclosed that prescription volumes for its Wegovy weight-loss tablet have surpassed three million since the oral formulation launched in early January.
